The Delhi High Court recently restored a single-judge order restraining Indian Pharma company Zydus Lifesciences from manufacturing, selling or marketing the product 'Sigrima' alleged to be a biological similar of a breast cancer drug produced by Switzerland-based F-Hoffmann-La Roche AG.